These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 22581753

  • 21. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.
    Schroeder GM, An Y, Cai ZW, Chen XT, Clark C, Cornelius LA, Dai J, Gullo-Brown J, Gupta A, Henley B, Hunt JT, Jeyaseelan R, Kamath A, Kim K, Lippy J, Lombardo LJ, Manne V, Oppenheimer S, Sack JS, Schmidt RJ, Shen G, Stefanski K, Tokarski JS, Trainor GL, Wautlet BS, Wei D, Williams DK, Zhang Y, Zhang Y, Fargnoli J, Borzilleri RM.
    J Med Chem; 2009 Mar 12; 52(5):1251-4. PubMed ID: 19260711
    [Abstract] [Full Text] [Related]

  • 22. Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors.
    Liu TC, Peng X, Ma YC, Ji YC, Chen DQ, Zheng MY, Zhao DM, Cheng MS, Geng MY, Shen JK, Ai J, Xiong B.
    Acta Pharmacol Sin; 2016 May 12; 37(5):698-707. PubMed ID: 27041462
    [Abstract] [Full Text] [Related]

  • 23. Design, synthesis, and biological evaluation of potent c-Met inhibitors.
    D'Angelo ND, Bellon SF, Booker SK, Cheng Y, Coxon A, Dominguez C, Fellows I, Hoffman D, Hungate R, Kaplan-Lefko P, Lee MR, Li C, Liu L, Rainbeau E, Reider PJ, Rex K, Siegmund A, Sun Y, Tasker AS, Xi N, Xu S, Yang Y, Zhang Y, Burgess TL, Dussault I, Kim TS.
    J Med Chem; 2008 Sep 25; 51(18):5766-79. PubMed ID: 18763753
    [Abstract] [Full Text] [Related]

  • 24. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
    Hayakawa M, Kawaguchi K, Kaizawa H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Parker P, Workman P, Waterfield MD.
    Bioorg Med Chem; 2007 Sep 01; 15(17):5837-44. PubMed ID: 17601739
    [Abstract] [Full Text] [Related]

  • 25. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y, Xin BT, Zhang Y, Wu J, Lu X, Zheng Y, Tang W, Zhou X.
    Eur J Med Chem; 2015 Jan 27; 90():170-83. PubMed ID: 25461318
    [Abstract] [Full Text] [Related]

  • 26. Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458).
    Liu L, Siegmund A, Xi N, Kaplan-Lefko P, Rex K, Chen A, Lin J, Moriguchi J, Berry L, Huang L, Teffera Y, Yang Y, Zhang Y, Bellon SF, Lee M, Shimanovich R, Bak A, Dominguez C, Norman MH, Harmange JC, Dussault I, Kim TS.
    J Med Chem; 2008 Jul 10; 51(13):3688-91. PubMed ID: 18553959
    [Abstract] [Full Text] [Related]

  • 27. Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR.
    Kendall JD, Giddens AC, Tsang KY, Frédérick R, Marshall ES, Singh R, Lill CL, Lee WJ, Kolekar S, Chao M, Malik A, Yu S, Chaussade C, Buchanan C, Rewcastle GW, Baguley BC, Flanagan JU, Jamieson SM, Denny WA, Shepherd PR.
    Bioorg Med Chem; 2012 Jan 01; 20(1):58-68. PubMed ID: 22177407
    [Abstract] [Full Text] [Related]

  • 28. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.
    Ashwell MA, Lapierre JM, Brassard C, Bresciano K, Bull C, Cornell-Kennon S, Eathiraj S, France DS, Hall T, Hill J, Kelleher E, Khanapurkar S, Kizer D, Koerner S, Link J, Liu Y, Makhija S, Moussa M, Namdev N, Nguyen K, Nicewonger R, Palma R, Szwaya J, Tandon M, Uppalapati U, Vensel D, Volak LP, Volckova E, Westlund N, Wu H, Yang RY, Chan TC.
    J Med Chem; 2012 Jun 14; 55(11):5291-310. PubMed ID: 22533986
    [Abstract] [Full Text] [Related]

  • 29. Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitors.
    Ma Y, Sun G, Chen D, Peng X, Chen YL, Su Y, Ji Y, Liang J, Wang X, Chen L, Ding J, Xiong B, Ai J, Geng M, Shen J.
    J Med Chem; 2015 Mar 12; 58(5):2513-29. PubMed ID: 25668160
    [Abstract] [Full Text] [Related]

  • 30. Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines.
    Lee J, Kim H, Yu H, Chung JY, Oh CH, Yoo KH, Sim T, Hah JM.
    Bioorg Med Chem Lett; 2010 Mar 01; 20(5):1573-7. PubMed ID: 20149658
    [Abstract] [Full Text] [Related]

  • 31. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
    Vallée F, Carrez C, Pilorge F, Dupuy A, Parent A, Bertin L, Thompson F, Ferrari P, Fassy F, Lamberton A, Thomas A, Arrebola R, Guerif S, Rohaut A, Certal V, Ruxer JM, Gouyon T, Delorme C, Jouanen A, Dumas J, Grépin C, Combeau C, Goulaouic H, Dereu N, Mikol V, Mailliet P, Minoux H.
    J Med Chem; 2011 Oct 27; 54(20):7206-19. PubMed ID: 21972823
    [Abstract] [Full Text] [Related]

  • 32. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
    Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H, Jewell JP, Kariv I, Katz JD, Kunii K, Lu W, Lutterbach BA, Paweletz CP, Qu X, Reilly JF, Szewczak AA, Zeng Q, Kohl NE, Dinsmore CJ.
    Cancer Res; 2010 Feb 15; 70(4):1524-33. PubMed ID: 20145145
    [Abstract] [Full Text] [Related]

  • 33. BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.
    Nourry A, Zambon A, Davies L, Niculescu-Duvaz I, Dijkstra HP, Ménard D, Gaulon C, Niculescu-Duvaz D, Suijkerbuijk BM, Friedlos F, Manne HA, Kirk R, Whittaker S, Marais R, Springer CJ.
    J Med Chem; 2010 Mar 11; 53(5):1964-78. PubMed ID: 20148563
    [Abstract] [Full Text] [Related]

  • 34. Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.
    Milkiewicz KL, Aimone LD, Albom MS, Angeles TS, Chang H, Grobelny JV, Husten J, Losardo C, Miknyoczki S, Murthy S, Rolon-Steele D, Underiner TL, Weinberg LR, Worrell CS, Zeigler KS, Dorsey BD.
    Bioorg Med Chem; 2011 Nov 01; 19(21):6274-84. PubMed ID: 21967808
    [Abstract] [Full Text] [Related]

  • 35. Design, synthesis and biological evaluation of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors.
    Liu Z, Wang R, Guo R, Hu J, Li R, Zhao Y, Gong P.
    Bioorg Med Chem; 2014 Jul 15; 22(14):3642-53. PubMed ID: 24882675
    [Abstract] [Full Text] [Related]

  • 36. Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.
    Li J, Li J, Zhang J, Shi J, Ding S, Liu Y, Chen Y, Liu J.
    Anticancer Agents Med Chem; 2020 Jul 15; 20(5):559-570. PubMed ID: 31893997
    [Abstract] [Full Text] [Related]

  • 37. Design, synthesis, and structure-activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.
    Tang Q, Zhao Y, Du X, Chong L, Gong P, Guo C.
    Eur J Med Chem; 2013 Nov 15; 69():77-89. PubMed ID: 24012712
    [Abstract] [Full Text] [Related]

  • 38. Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors.
    Han SY, Choi JW, Yang J, Chae CH, Lee J, Jung H, Lee K, Ha JD, Kim HR, Cho SY.
    Bioorg Med Chem Lett; 2012 Apr 15; 22(8):2837-42. PubMed ID: 22450128
    [Abstract] [Full Text] [Related]

  • 39. Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.
    Liu L, Norman MH, Lee M, Xi N, Siegmund A, Boezio AA, Booker S, Choquette D, D'Angelo ND, Germain J, Yang K, Yang Y, Zhang Y, Bellon SF, Whittington DA, Harmange JC, Dominguez C, Kim TS, Dussault I.
    J Med Chem; 2012 Mar 08; 55(5):1868-97. PubMed ID: 22320327
    [Abstract] [Full Text] [Related]

  • 40. Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.
    Kulagowski JJ, Blair W, Bull RJ, Chang C, Deshmukh G, Dyke HJ, Eigenbrot C, Ghilardi N, Gibbons P, Harrison TK, Hewitt PR, Liimatta M, Hurley CA, Johnson A, Johnson T, Kenny JR, Bir Kohli P, Maxey RJ, Mendonca R, Mortara K, Murray J, Narukulla R, Shia S, Steffek M, Ubhayakar S, Ultsch M, van Abbema A, Ward SI, Waszkowycz B, Zak M.
    J Med Chem; 2012 Jun 28; 55(12):5901-21. PubMed ID: 22591402
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.